ReAlta Life Sciences
Biotechnology ResearchView the employees at
ReAlta Life Sciences-
samuel massoni Founding Partner, New England Peptide, Peptides International at NEP
-
Top 5%
Alana Sampson Research Associate II-
Top 10%
Ryan Farrell Staff Accountant - ReAlta Life Sciences, Inc.-
Top 10%
Kenji Cunnion Chief Medical Officer at ReAlta Life Sciences, Inc.-
Norfolk
-
Top 5%
Ulrich Thienel Chief Executive Officer at ReAlta-
Norfolk, Virginia, United States
-
Top 10%
Overview
ReAlta Life Sciences is a clinical-stage biotech company dedicated to harnessing the power of the immune system to address life threatening acute inflammatory and rare diseases. ReAlta’s EPICC peptides are based on research into the human astrovirus, HAstV-1, which causes a non-inflammatory, self-limiting gastroenteritis unique among viruses by inhibiting components of the innate immune system. ReAlta’s therapeutic peptides leverage these virus-derived mechanisms to rebalance complement and inflammatory processes in the body. The company’s pipeline is led by RLS-0071, which has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and European Medicines Agency for the treatment of hypoxic-ischemic encephalopathy (HIE) in neonates. The company launched in 2018, and is located in Norfolk, Virginia. For more information, please visit www.realtalifesciences.com or contact us at info@realtalifesciences.com.
-